Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates
MVA-vectored universal beta-coronavirus vaccine design & development
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates
Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization - Harvala - 2022 - Transfusion - Wiley Online Library
A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates - ScienceDirect
COVID-19 vaccine - Wikipedia
The bivalent vaccine D614 + Beta elicits cross-neutralization of the
Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates
Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
COVID-19 vaccine - Wikipedia
